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Introduction
Thuja occidentalis, commonly known as Arbor vitae or white
cedar, is indigenous to eastern North America and is grown in
Europe as an ornamental tree (1). The plant was first identified
as a remedy by native Indians in Canada during a 16th century
expedition and was found to prove effective in the treatment of
weakness from scurvy (2). In folk medicine, Thuja occ has
been used to treat bronchial catarrh, enuresis, cystitis, psoriasis,
uterine carcinomas, amenorrhea and rheumatism (3–6). Today,
it is mainly used in homeopathy as mother tincture or dilution
(7,8). In combination with other immunomodulating plants,
such as Echinacea purpurea, Echinacea pallida and Baptisia
tinctoria, this medicinal plant is also used as evidence-based
phytotherapy for acute and chronic infections of the upper res-
piratory tract (9,10), and as an adjuvant to antibiotics in severe
bacterial infections such as bronchitis, angina, pharyngitis,
otitis media and sinusitis (11,12).
Several reviews and monographs describe the botany,
constituents and some pharmacological properties, and the use
of this herbal substance in the treatment of the common cold
(3,13–17); however, the majority are old or written in German.
Therefore, we aimed to compile an up-to-date, comprehensive
and evidence-based review of Thuja occ that covers its
botanical description, phytochemistry, in vitro and  in vivo
pharmacology, safety and efficacy. For this purpose, MED-
LINE databases were searched and manufacturers of Thuja-
containing preparations were contacted for further details or
unpublished data.
Botanical Description
Thuja occidentalis was originally cultivated in North America.
It is a native European tree with a maximal height of 15–20 m
(Fig. 1). It has coniferous pyramidal features, with flattened
branches and twigs in one plane, bearing small scale-like
leaves (3). Over the whole year, the leaves are green, with the
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contain the seeds.
Ethnobotany
Previously, the genus Thuja (family: Cupressaceae) was con-
sidered to consist of the species Thuja koraiensis Nakai, Thuja
occidentalis, Thuja orientalis L. and Thuja plicata D. Don
(15,18) which are commonly cultivated in Central Europe.
However, more recent findings define the genus as follows:
T.koraiensis,T.occidentalis,T.plicata,Thuja standishii (Gordon)
Carr. and Thuja sutchuenensis Franch. Traditional names are
American arborvitae, Arbor vitae, Arborvitae, Eastern white
cedar, Hackmatack, Northern white cedar, Swamp cedar,
Thuja, Tree of Life, white cedar and yellow cedar in English,
and abendländischer Lebensbaum, amerikanischer
Lebensbaum, Heckenthuja, Lebensbaum (German), Livsträ
(Danish), Thuya d’occident (French), Thuia (Italian), Tuja
(Russian), Livsträd (Swedish) and Zerav zapadni (Czech) (19).
Macroscopically, the cut herb shows small flattened, green
twigs bearing paired, decussate leaves ~3 mm long. The keeled
alternately lateral pairs partly conceal the flat rhomboidal,
facial pairs pressed close together. The odour and taste
are strongly camphoraceous (3). Only the dried twig tips of the
species Thuja occ are used in the drug Thujae occidentalis
herba. This consists of the varieties of Thuja occ: Thuja occ
cv.  Aureospica, Thuja occ cv.  Lutea, Thuja occ cv.
Vervaeneana and Thuja occ cv. Wareana (20). The cut herb
should contain no more than 2% of the stem over a 4 mm
diameter (Fig. 2). Table 1 presents the general description and
distinguishing features of the four varieties.
Phytochemistry
The fresh plant (related to the dry substance) contains 0.6%
essential oil, 2.07% reducing sugar, 4.9% water-soluble
polysaccharides, 2.11% water-soluble minerals, 1.67% free
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Figure 1. Typical twigs ad leaves of Arbor vitae (Thuja occidentalis). The
figure shows the flattened branches and small coniferous pins containing
the seeds.
Figure 2. For the therapy, the dried herbal substance is used, which is called Thujae occidentalis herba. This figure shows details of the macroscopic appearance
of the dried twig trips for the four variations Thuja occ cv. Aureospica, Thuja occ cv. Lutea, Thuja occ cv. Vervaeneana and Thuja occ cv. Wareana.acid and 1.31% tannic agents (14). The essential oil of the
fresh leaves (related to the monoterpene fraction) contains
65% thujone, 8% isothujone, 8% fenchone, 5% sabines and
2%  -pinen as the main monoterpenes (14). Other monoter-
penes, namely carvotanacetone, origanol, origanes, myrcen
and camphen, have been described (14,21–23). Recently, further
bioactive constituents have been found (1). High molecular
weight glycoproteins/polysaccharides are highly relevant for
the activity of the plant (16).
The constituents of the dried herbal substance Thujae
occidentalis herba are listed in Table 2 (14,15,24–30). According
to Hänsel et al. (15), the drug contains 1.4–4% essential oil,
60% of which is thujone, which corresponds to 2.4% thujone
in the whole drug. Thujone occurs in nature as a mixture of 
 - and  -isomers (31,32). According to the European Agency
for the Evaluation of Medicinal Products (EMEA), the content
of thujone in dried twigs was determined as 7.6 mg/g, consisting
of 85%  -thujone and 15%  -thujone (Fig. 3). The equilibrium
mixture consists of 33%  -thujone and 67%  -thujone (27).
A critical factor for Thuja’s use as a medicinal herb is its
content of essential oil. Indeed, the content of thujone seems to
be significantly affected by different extraction procedures.
The highest content of essential oil was found in extracts
obtained by distillation, whilst percolation with purified water
reduced the thujone content in the extract to the lowest level
(29). Using purified water as a solvent, an average of 0.6 mg
of thujone was extracted from 1 g of drug during percolation
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Table 1. The natural habitat of the herbal substance Thujae occidentalis
herba including the four varieties Thuja occ cv. Aureospica, Thuja occ cv.
Lutea, Thuja occ cv. Vervaeneana and Thuja occ cv. Wareana)
Variety General description
Thuja occidentalis Branchlets: the branchlets are flattened, dark green
on the upper side and light-green or brownish on
the base but without whitish markings. They all lie
on the same plane, lateral sprouts of the last order
with reference to the mother axis apical branching
mostly to one side.
Leaves: the leaves are differentiable into surface
and marginal leaves. The visible leaf parts on the
upper side of the branchlets are weakly convex;
the under side of the branchlets is weakly concave.
Surface leaves are characterized by a broad keel,
greatly narrowing toward the tip. The tip is blunt to
sharply pointed and slanted toward the sprout.
Marginal leaves scaffold mostly pressed against the
flanks of the surface leaves or the keels of the next
higher marginal leaves. The marginal leaf margins
are usually not in contact with the overlying
surface leaf. They only run parallel to it for a short
distance. Surface leaf tips extend beyond or just as
far as the marginal leaf tips.
Oil reservoirs: they are raised and lying on the 
keels of the surface leaves; present on the marginal 
leaves but not raised.
Differentiating feature
Thuja occidentalis cv. Yellowish color, oil reservoirs less clearly raised,
Aureospica secondary leaf tips generally not extending beyond 
the marginal leaf tips, shinier.
Thuja occidentalis cv. Broader sprouts (ratio L/B   0.70), marginal leaf 
Lutea margins further apart, more densely branched,
yellowish color.
Thuja occidentalis cv. ‘Joints’longer, surface leaf tips usually extend 
Vervaeneana clearly beyond the marginal leaf tips (ratio:
L/B   1.66). Marginal leaf edges over surface
leaves usually run parallel for a longer distance,
oil glands often also raised on the marginal 
leaf keels. Cuticle thicker showing multiple 
cracks.
Thuja occidentalis cv. Broader sprouts (ratio: L/B   0.78), more densely 
Wareana branched, cuticle thicker and showing multiple 
cracks.
Table 2. The constituents of the dried herbal substance Thujae occidentlis
herba
Group Constituents
Essential oil (1.4–4% Borneol
of drug) Camphene
Fenchone
Limonene
Myricene
 -Terpine
Terpinolene
Thujone (0.76–2.4% of essential oil, 85% 
 -thujone, 15%  -thujone)
Thujylalcohol
Coumarins p-Coumaric acid
Umbelliferone
Flavonoids ( / )-Catechine
( )-Gallocatechine
Kaempherol
Kaempherol-3-O- -rhamnoside
Mearnsitrin
Myricetine
Myricitrin
Procyanidin B-3
Prodelphinidin
Quercetin
Quercitrin
Other Tannic acid (~1.3% of drug)
Thuja polysaccharides and proteins (~4% of drug)
Figure 3. Thujone, which consists of 85%  -thujone and 15%  -thujone, is
the major constituent in the essential oil from the dried herbal substance
Thujae occidentalis herba.(30). In contrast, when 30% (v/v) ethanol was used, 2.8 mg of
thujone was extracted from 1 g of Thujae occidentalis herba,
and   2.5-fold higher amounts of thujone (7.9 mg) were
attained with high ethanol concentration (90% v/v) (30). From
the result of 12 batches, the mean value for the thujone content
was 1.16 mg/g of herbal substance and the maximum value
was 2.95 mg/g, corresponding to 0.30%. Using a special
extraction procedure with 30% (v/v) ethanol, the content of
thujone in the extract can be reduced to one-third of the
amount obtained by extraction with ethanol 90% (v/v) (Fig. 4).
Pharmacological Properties
The immunopharmacological potential of Thuja has been
investigated in various in vitro and in vivo test models (33–35).
Of the many existing studies on this subject, only the most
relevant in vitro and in vivo investigations will be described in
greater detail in the following.
In Vitro Studies
HIV-1 Activity
Thuja polysaccharides (TPS) inhibited human immunonodefi-
ciency virus (HIV)-dependent cell death at a final concentration
of 625  g/ml. At this concentration, TPSg was shown to be
completely non-toxic for MT-4 cells, which had not been
infected with HIV-1. TPS were shown to inhibit HIV-1-specific
antigen expression on freshly infected MT-2 cells in a dose-
dependent manner (36,37).
Spleen Cell Proliferation
The  Thuja retentate fraction (obtained by dialysis of an
aqueous-ethanolic extract of Thuja occ cut-off: 10 000 Dan,
Amicon SP20, S10Y10) caused an increase in the prolifera-
tion rates of spleen cells from NMRI and C3H/HeJ mice. In
comparison with the medium control, a significantly higher
incorporation rate was found up to a concentration of
7.8  g/ml. The maximum stimulation indices were 5.3 in the
tests with spleen cells from NMRI mice. In the tests with
C3H/HeJ spleen cells, stimulation index (SImax) values of 3.4
were reached (38).
CD4-positive T Cells
Polysaccharide fractions with mol. wts ranging from 20 000 to
 1 000 000 Da were isolated from the aqueous alkaline extract
of the herbal parts of Thuja occ by ethanol precipitation
and fractionation by ultrafiltration. High molecular weight
subfractions of TPS proved to be highly mitogenic on peripheral
blood leukocytes. It was demonstrated that the mitogenic and
cluster-forming activity of TPS causes T-cell induction partic-
ularly of the CD4-positive T-helper/inducer cells in connection
with an increased production of interleukin-2 (IL-2). This
indicates that not only proliferation but also a differentiation to
fully functional T-helper cells takes place. Only T cells, not
B cells, were stimulated by TPS. The activation occurred only
in the presence of the monocyte/macrophage fraction and was
neutralized by antibodies against interferon (IFN)-  and IL-1.
TPS-induced IFN-  production in CD4  cells was assumed to
be the mode of action, whereby the IFN-  produced stimulated
monocytes/macrophages to produce IL-1. As a second signal
of the T-cell activation, this triggered the expression of IL-2
receptors and the production of IL-2 in CD4  T-helper cells
(39,40).
Cytokine Induction
The incubation of P388C mouse macrophages with
10–100  g/ml of the retentate fraction from Thujae occidentalis
herba led to an increased secretion of the cytokines IL-1, IL-6
and tumor necrosis factor-  (TNF- ) in the cell culture super-
natant.With regard to TNF- , the retentate fraction from Thuja
showed concentration-dependent activity (38).
These results were confirmed in cell culture assays with
human blood monocytes, where incubation with the Thuja
retentate fraction also induced a significant increase in IL-1,
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Figure 4. The solvent for extraction significantly influences the amount of thujone in the extracts of the dried herbal substance Thujae occidentalis herba.IL-6 and TNF- secretion. The cytokine titers in the supernatants
were higher than the titers induced by phytohemagglutinin
(PHA; 10  g/ml).
After incubation of NMRI spleen cells with the Thuja reten-
tate fraction, an increase in the production of IFN    was
observed. After application of the Thuja retentate, a maximum
of 19 U/ml IFN    was determined in the cell culture super-
natants, whereas no IFN    activity was detected in the
supernatants from the medium control. Activity was also shown
for the positive control substance concanavalin A which induced
an IFN    production of 19 U/ml at a concentration of 2  g/ml.
Antibody Production
The retentate fraction produced a concentration-dependent
increase in the number of antibody-producing lymphocytes in
the hemolytic plaque assay in vitro. The number of anti-SRBC-
(sheep red blood cell)-IgM-producing plasma cells rose, as did
all Ig-secreting plasma cells, as registered by the ‘reverse’
technique using protein A-labeled SRBCs. Incubation with
lipopolysaccharide (LPS) as positive control also led to a
concentration-dependent increase in the number of plaque-
forming cells (41).
NO2
  Production
The influence of Thujae occidentalis herba on the oxidative
metabolism of macrophages was determined by measuring the
NO2
  production of mouse alveolar macrophages (MH-S) after
48 h incubation with the respective test fractions. The NO2
 
production of the MH-S cells was increased by incubation with
the retentate fraction in a concentration-dependent fashion from
2   0.3  mol/l (medium control) to a maximum of 42.5  
2.7 mol/l. The combined addition of IFN and LPS (1   5 ng/ml)
served as a positive control in this test system (Fig. 5) (38).
The results of the in vitro investigations indicate an
immunomodulatory and antiviral potential of Thuja occ. The
main target of the immunologically active constituents seems
to be the macrophage/monocyte fraction. The activation of
macrophages manifested itself in increased cytokine secretion
and the stimulation of NO2
  production. The presence of
macrophages was a prerequisite for the activation of CD4-
positive T cells, thus indicating a decisive role for macrophages
also for the observed effects in spleen cell cultures i.e. stimu-
lation of cell proliferation and antibody production.
In Vivo Studies
Leukocyte Counts in Mice
A single dose of Thuja extract (i.v.) led to a dose-dependent
left shift in white blood counts within 4 h. The segmented and
stab granulocytes in the blood of the animals receiving the
extract increased 3- to 4-fold compared with the control
animals. The percentage of segmented granulocytes increased
from 9 to 36%, and the percentage of stab granulocytes from
3 to 15%. Correspondingly, the number of lymphocytes
decreased in comparison with the control mice (from 89 to
48%). The effects were transitory, i.e. the blood count had
normalized after 15 h at the latest (38).
Cytokine Induction
The i.v. administration of a retentate fraction of Thujae
occidentalis herba induced a significant increase in TNF- ,
IL-6 and IL-1 activity in the serum of treated mice compared
with control mice that had received physiological NaCl only.
The only dose dependency was found with regard to the induc-
tion of IL-6 and IL-1 (38).
Stimulation of cytokine production could also be seen in
irradiated mice after i.v. application of Thuja TPSg fraction.
CBF1 female mice were irradiated with 3 or 6 Gy at a dose rate
of 17 cGy/min. A total of 144 mice were given an i.v. injection
of TPSg. Forty-eight control mice were injected with RPMI-
1640 medium alone. At 4–15 days after TPSg injection, the
mice were sacrificed and tested for the number of c.f.u.-GM
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Figure 5. Increase in the NO2 production of alveolar macrophages through the retentate fraction from Thuja occidentalis herba (100, 10 and 1  g/ml). Positive
control substance: LPS (5 ng/ml)   IFN-  (1 ng/ml). Data are expressed as the mean value   SD (n   4).and c.f.u.-S from both bone marrow and spleen. Seven days
after i.v. injection of 2.5 mg of TPSg per mouse, the titers of
c.f.u.-GM, c.f.u.-S-8 and c.f.u.-S-11 in the bone marrow and
spleen of 3- or 6 Gy-irradiated and TPSg-treated mice were
significantly increased (P   0.01) compared with irradiated
mice not receiving TPSg (42).
After oral application of an aqueous-ethanolic extract of a
mixture of Thujae occidentalis herba, Baptisiae tinctoriae
radix, Echinaceae purpureae radix and Echinaceae pallidae
radix, there were no recognizable differences in the cytokine
titers [IL-2, IFN- , granulocyte–macrophage colony-stimulating
factor (GM-CSF), IL-1 and TNF- ] between sera of NMRI
mice that had been treated perorally with the herbal extract for
a period of 1–9 days and the sera of the control mice.
Concentrations of cytokines in sera of both groups ranged
around the detection limit of the respective assays. Spleen cells
from NMRI mice, however, that had been treated with the
extract for 1–9 days produced higher amounts of IL-2, GM-CSF
and IFN-  ex vivo in comparison with those from the control
mice especially after additional stimulation by LPS or con-
canavalin A in vitro. Application of the extract also triggered
the production of IL-1 and TNF-  by peritoneal macrophages
ex vivo, particularly after co-stimulation with LPS ex vivo, thus
mimicking the action of microbial antigens, such as bacterial
LPS, in the case of infections (43).
Thus the peroral administration of the Thuja-containing
preparation did not induce any systemic increase in cytokine
titers, but probably caused a local activation of cytokine-
producing cells for ‘priming’. Thus, after local contact with the
immunomodulatory active components of the extract in the gut
or in the upper part of the bronchial system, cells are able to
react to an additional stimulation causing increased cytokine
secretion. Under physiological conditions, such a local modula-
tory cytokine induction is to be assessed more positively than a
systemic one, which in the case of an overexpression could
cause considerable side effects (43).
Antibody Response in Normal and Immunosuppressed Mice
Oral application of the extract significantly enhanced antibody
response to SRBCs in healthy NMRI mice, inducing an
increase in numbers of splenic plaque-forming cells (PFCs) and
titers of specific antibodies in sera from treated mice. In mice
immunosuppressed by old age or additional treatment with
hydrocortisone, treatment with the extract resulted in a normal-
ization of antibody response to SRBCs.
To prove the hypothesis of a gut-associated lympho-
epithelial tissue (GALT) activation, the effects of Thuja on
immunoreactivity of Peyer’s patches (PP) cells was investig-
ated by measuring the anti-SRBC antibody response of PP
cells ex vivo using the hemolytic plaque technique. For this
purpose, a Thuja retentate fraction was administered by gavage
to five mice at a dose of 1 mg. Mice in the control group
received a corresponding amount of matrix without test sub-
stance. After 15 h, mice were sacrificed and the PP cells were
isolated and incubated with medium, LPS or the Thuja retentate
fraction on cell culture plates. The number of antibody-
producing cells was determined after 7 days using the reverse
hemolytic plaque technique. The extract significantly
enhances antibody response to SRBCs in PP, thus indicating
that immunologically active macromolecules can contact cells
of GALT and modulate the mucosal immune response (43,44).
Immune Response in Mice after Long-term Treatment
The effects of an orally administered aqueous-ethanolic extract
of a mixture of Thujae occidentalis herba, Baptisiae tinctoriae
radix, Echinaceae purpureae radix and Echinaceae pallidae
radix on the immune response in mouse were investigated
over the short and long term. In all investigated mouse strains,
the extract induced an increase in the numbers of PFCs and in
the titers of specific antibodies in the sera of treated mice.
Administration of the extract over several months also stimu-
lated the PFC response without affecting spleen weight, total
cell yield per spleen or white blood cell count (41).
Influenza Virus Type A Infection in Mice
The effects of oral application of an aqueous-ethanolic extract
of a mixture of Thujae occidentalis herba, Baptisiae tinctoriae
radix, Echinaceae purpureae radix and Echinaceae pallidae
radix on the course of influenza A virus infection was investig-
ated in Balb/c mice. The mixture extract was administered to
mice via their drinking water for 14 days, starting 6 days
before intranasal infection with influenza A virus. The extract
induced a statistically significant increase in survival rates,
prolonged mean survival time and reduced lung consolidation
and virus titers. The experiment demonstrated that the plant
immunomodulator given 6 days before exposure is a potent
inhibitor of influenza A virus pathology in vivo.
Because of the proven immunomodulatory efficacy of the
preparation, it was assumed that the positive effect of this
extract exerted on infected mice is mediated first of all by its
immunostimulating activity and that the direct antiviral activ-
ity is rather of secondary importance (45).
Clinical Efficacy
While there are many pre-clinical investigations in the literature,
no data on clinical trials using Thuja occ as a single herbal sub-
stance are available. In contrast, many clinical studies have
been conducted with a herbal medicinal product containing an
aqueous-ethanolic extract of a mixture of Echinacea purpurea,
Echinacea pallida, Baptisia tinctoria and Thuja occ [Esberitox®,
Schaper & Brümmer, Salzgitter, Germany (33,34)]. In most of
these studies, the therapeutic efficacy of the Thuja-containing
herbal product was proven in the treatment of acute respiratory
tract infections and the common cold. Two of these pre-GCP
(Good Clinical Practice) clinical trials showing good thera-
peutic efficacy of the herbal product on viral upper respiratory
tract infections (URIs) are particularly noteworthy. One
randomized, placebo-controlled, double-blind study enrolled
100 subjects (10). After just 3 days, the patients from the active
74 Properties of Thuja occidentalis (Arbor vitae)treatment group showed significant improvements in their
common cold symptoms. In the other randomized, placebo-
controlled, double-blind study (9), 150 patients with URIs
were treated with either Esberitox or placebo. In this latter
study, Esberitox showed a similar efficacy result on URI
symptoms to that in the former study. In addition, a significant
enhancement of the immune response was observed in recall
antigens. In four other studies, the herbal product was also
found to be beneficial when used as an adjuvant to antibiotic
treatment of bacteria-induced URI (11,12,46,47). In the
following section, only the more recent and GCP-compliant
studies are discussed in detail.
Common Cold
In a double-blind, placebo-controlled multicenter study (15
practitioners in Germany), patients suffering from acute com-
mon cold were randomized to receive Esberitox (Thuja daily
dose corresponding to 6 mg three times daily (t.i.d.)] or
placebo for 7–9 days (48). On a daily basis, the patients docu-
mented the intensity of 18 cold symptoms and their overall
cold status on a 10-point scale and rated their general well-
being using Welzel–Kohnen color scales. Additionally, a
physician assessed the severity of illness on days 4 and 8 using
the Clinical Global Impression (CGI-1). The main and confir-
matory outcome measure was expressed as a total efficacy
value. This was gauged from the z-standardized area under the
curve (AUC) values of the primary end-points (rhinitis score,
bronchitis score, CGI-1 and general well-being). Adverse
events, overall tolerability, vital signs and laboratory parame-
ters were documented. A total of 259 patients were eligible to
be evaluated (intention to treat; ITT). The primary efficacy
parameters demonstrated the herbal product’s superiority over
placebo (P   0.05). The effect size was 20.6% of the SD [90%
confidence interval (CI) 0.04–41.1] in the ITT population and
23.1% (1.7–44.5) in the valid case population. In relation to
general well-being, the effect size was 33.9% of the SD
(12.5–55.3%,VC). The efficacy of the drug was most prominent
in the subgroup of patients who started therapy at an early
stage of their cold or with a symptom score of  4 (Fig. 6). In
the drug group, patients suffering symptoms of at least moder-
ate intensity at baseline showed a response rate (at least 50%
improvement of the global score, day 5) of 55.3%, and those
in the placebo group showed a response rate of 27.3%
[P   0.017; number needed to treat (NNT)   3.5]. This study
showed the therapeutic benefit and superiority of Esberitox
versus placebo for decreasing the duration of the common cold
and alleviating symptoms. A greater benefit can be expected if
patients with the common cold are able to start taking the drug
as early as practicable after manifestation of initial symptoms.
In another double-blind, placebo-controlled study, 94 adults
(age  18 years) suffering from the common cold for no
longer than 1 day were randomized to two different treatment
groups: active substance (the Thuja daily dose corresponding
to 6 and 12 mg t.i.d) or placebo (49). The results of the primary
efficacy criteria for evaluation (reduction of total number of
tissues used throughout the entire observational period) were
confirmed to be statistically significant and clinically relevant.
This was true for both the ITT analysis (P   0.0259) and the
per protocol analysis (P   0.0146). Subsequent pairwise
group comparisons showed a statistically significant superior-
ity of the high dose compared with placebo (P   0.0323).
Similar results were obtained for the secondary efficacy
parameters such as the number of tissues used on day 2
(P   0.0071) and day 5 (P   0.0495). From these results, it
can be concluded that the clinical efficacy of the Thuja-
containing herbal medicinal product has been confirmed for
the treatment of acute common cold.
Supportive Therapy to Standard Antibiotics
Many antibiotics are known to have a suppressive effect on the
immune system. A total of 53 patients scheduled to receive
antibiotics for treatment of acute exacerbation of chronic
bronchitis (as an example of a severe bacterial infection requir-
ing antibiotics) were enrolled in a prospective, multicenter,
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Figure 6. Improvement of rhinitis scores (congested nose, runny nose, sniffling, frequency of handkerchief use, frequency of sneezing). Mean symptom 
scores (baseline adjusted mean and SE) are shown for placebo (n   57) and the Thuja-containing herbal remedy (n   58). P-values for the differences between
treatment groups are given for the patients with a symptom score of  4 at day 1 (repeated measures; co-variates at day 1).double-blind, placebo-controlled study (50). The aim of this
research was to confirm any beneficial effects of the co-med-
ication of antibiotics with the drug in subjects with acute exac-
erbation of chronic bronchitis. The main inclusion criteria
were chronic bronchitis, staged to forced expiratory volume of
the first second (FEV1) with a value between 35 and 75%.
Patients were randomly assigned to receive antibiotics plus
either the herbal product (Esberitox, n   25; Thuja daily dose
corresponding to 12 mg t.i.d.) or placebo (n   27). Antibiotic
therapy was administered according to generally accepted
guidelines and the study medication was given concomitantly
for 28 days. The baseline-adjusted means for FEV1 (%) on day
10 were 68.7 points for the drug group and 59.2 points for the
placebo group (P   0.0303), showing a faster improvement in
the drug group. For FEV1, the difference between the two
treatment groups was 267 ml (P   0.0499). The time to half-
maximal improvement was 5.7 days in the drug group com-
pared with 12.8 days in the placebo group.
Clinical Safety
Symptoms of intoxication from the fresh Thuja plant include
vomiting, stomach ache, diarrhea and gastroenteritis followed
by absorption disorders, headache, nervous agitation and
chronic convulsions, and symptoms of liver and renal toxicity
extending to yellow liver atrophy, arrhythmia and myocardial
bleeding (51). In cases of overdose and abuse, the oral intake
of  Thuja extracts induced severe metabolic disturbances.
Intoxication was accompanied by an irritant effect on the
gastrointestinal tract, uterus, liver and kidney. Infants who
ingested leaves and twigs of fresh plant showed mild gastroin-
testinal disorders and vomiting (24).
These reactions can be explained by the high contents of
thujone in the fresh plant. This ingredient occurs in significant
quantities in the essential oil fraction Thuja occ (see
‘Phytochemistry’above) and many other plants that are part of
the human diet such as Salvia folium, widely used as spice and
in teas, or Artemisia pontica, for the production of vermouth
wine (52). Thujone is reported to be the toxic agent in
absinthe, a liqueur popular in the 19th and early 20th centuries,
and to have antinociceptive, insecticidal and anthelmintic
activity (53). The acute toxicity information available for
thujone was reported as follows (LD50 in mg/kg): rats oral,
500; rabbit i.v., 0.031; rabbits dermal, 5000. The lethal dose
appeared at 0.2 ml/kg body weight (BW) (54). In other invest-
igations, porphyrogenic properties or mitogenic activities
were reported (55,56). The Committee on Veterinary
Medicinal Products noted that the LD50 values stated for the
constituent thujone were 87.5 mg/kg of BW after subcutaneous
administration in mice and 240 mg/kg BW after intraperi-
toneal administration to rats (24). In an in vitro investigation,
however, thujone was demonstrated to be non-toxic (57) and
an oral dose of up to 1.25 mg thujone/kg BW is considered
harmless in humans (58). Up to a single daily dose of 75 mg is
reported to be safe in humans. In their opinion issued on
2 December 2002, the Scientific Committee of the European
Commission stated that a 60 kg adult who consumes one litre
of an alcoholic beverage containing 5 mg/l thujone, i.e. the
maximum permitted level of thujone in alcoholic beverages
with up to 25% alcohol, would ingest ~0.08 mg thujone/kg
BW. This intake is ~100 times lower than the no effect level
(NOEL) derived from a 14 week study in rats (59).
Adverse Events in Clinical Trials
The safety of Thuja-containing preparations especially those
extracts percolated with ethanol 30% (v/v) can be regarded as
good. In a randomized, double-blind, placebo-controlled study,
26 patients receiving Thuja and 23 patients receiving placebo
showed adverse events (48). Adverse drug reactions (ADRs)
were suspected in five patients in the placebo group and in two
patients in the active treatment group [one adverse event in the
drug group (sleeplessness) was deemed possibly related to the
study medication]. No serious adverse event occurred. In
another study, 19 mild to moderate adverse events (drug   8,
placebo   11) in 14 subjects were documented (50). None of
them was assessed as serious and no event was classified as an
ADR. In a recent double-blind study, no adverse events were
reported (49). The investigators concluded that the herbal
product can be recommended as a safe treatment for acute viral
respiratory tract infections. In addition, no adverse events were
reported in another study (60). One study (9) showed that three
patients of both study groups experienced mild nausea.
Additionally, one patient treated with the Thuja-containing
preparation complained of rheumatic symptoms and one patient
from the placebo group reported heartburn. All adverse events
were classified as ‘mild’to ‘moderate’and judged to be unrelated
to the study medications.
Pregnancy and Lactation
Thujone-containing plants and preparations do not have direct
or indirect abortive effects (52). Like many other herbs, decoc-
tions of Thuja have traditionally been used for its abortive
properties, presumably mixed with Savin tops (15). Such trials
have been carried out repeatedly by laymen, but have failed
nearly every time to prove any abortive properties and have
often resulting in lethal toxicity. Deadly apnea can occur if
large quantities of thujone are absorbed by the circulatory sys-
tem (14). Over the many years of experience with Esberitox,
no such safety concerns have been reported. For medical prac-
tice, however, it is recommended that Thuja not be used during
pregnancy and lactation before consulting a doctor.
Post-marketing Data
Our search shows that Thuja is only used phytotherapeutic-
ally in the product Esberitox, a herbal medicinal product that
has been marketed throughout the world for many decades.
Considering the last 5 years of marketing (January
1999–August 2003), the distribution of the number of sold
and/or prescribed packages of the herbal product corresponds
to a total amount of 1150 million units (1 unit corresponds to
76 Properties of Thuja occidentalis (Arbor vitae)2 mg of Thuja). Assuming an average of 7–14 days of treat-
ment with the maximum dosage (18–36 mg Thuja) as directed,
this corresponds to 12.2 million treated patients in the covered
period worldwide. During these periods, a total of 63 ADR
reports with Esberitox were recorded. The majority of the
ADRs were of a mild and transient nature. Classified by organ
systems, skin and appendage disorders, such as skin rashes,
were reported most frequently. This corresponds to an incidence
of about five ADRs per 1 million treated patients. During this
period, only one case of a serious and unexpected ADR of
acute sarcoidosis (Löfgren’s syndrome) was reported in the
literature (61). Since the woman had injected a mistletoe
preparation in addition to Esberitox, with a positive lympho-
cyte transformation test (LTT), a causal relationship with the
Thuja-containing herbal product was assessed as ‘unlikely’.
The recommended daily dose of Esberitox in adults is a dose
corresponding to 18–36 mg of Thuja. Children should take
12–24 mg. This is equivalent to a daily dose of 18–36  g of
thujone for adults and 12–24  g for children. This daily dose
is several orders of magnitude below the threshold of 1.25 mg
thujone/kg BW considered harmless for humans, and also
below the maximum level of thujone permitted in alcoholic
beverages (~0.08 mg thujone/kg BW for an adult).
Summary and Conclusion
Thuja occidentalis is widely used in homeopathy and evidence-
based phytotherapy. Its immunopharmacological potential has
been demonstrated in numerous in vitro and in vivo test models
showing its immunostimulating and antiviral activities. A crit-
ical factor for Thuja’s use as a medicinal herb is its content of
thujone, which is reported to be the toxic agent of many fresh
plants that are part of the human diet. However, the content of
thujone in Thuja-containing finished products depends on the
extraction procedure; thus it was shown that percolation with
ethanol 30% (v/v) can significantly reduce the thujone content
in comparison with the percolation by using ethanol 90% (v/v)
for extraction. Three GCP-compliant, double-blind, placebo-
controlled clinical studies have verified the efficacy and safety
of a herbal medicinal product containing Thuja (Esberitox) for
treatment of the common cold, and its efficacy as an adjuvant
to standard antibiotic treatment of severe bacterial infections.
In these studies, only mild to moderate adverse events were
documented with a rare frequency, and none were assessed as
serious. Based on the recommended daily dose and the manu-
facturing procedure, the amounts of thujone that would be
ingested are well below the threshold limit values considered
harmless for humans, and even below the maximum permitted
level in alcoholic beverages. Over the past 5 years,  12 mil-
lion patients have been treated with this herbal medicinal prod-
uct worldwide. During the same period, ADRs of a mild to
moderate nature were reported with a rare frequency, but none
was judged to be relevant to the safety of the herbal product.
Thus, it can be concluded that due to a special extraction
procedure, this  Thuja-containing preparation is a safe and
effective herbal medicinal product for treatment of the common
cold. The recommended daily dose of up to 36 mg of Thuja is
within a safe and non-critical range. Notwithstanding these pos-
itive data, further comprehensive evidence from clinical trials,
especially with the herbal substance alone, is still needed.
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